SSelectStock

INDOCOIndoco Remedies Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)

Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, the company offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. Additionally, it provides contract research services, such as custom chemical synthesis of molecules and intermediates; process chemistry research and development; non-infringing process designing and scale up; and analytical method development, validation, impurity characterization, and polymorphic studies, solutions, as well as intellectual property management. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.

263.02
3.45%
58Decent

Mkt Cap
₹2,424 Cr
P/E
797.0
P/B
2.3
Div Yield
0.08%
52W High
₹332.20
52W Low
₹162.19

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)2,424.30
P/E797.03
P/B2.31
PEG
ROE %-10.10
ROCE %0.80
Debt / Equity1.17
EPS0.33
Revenue Growth %6.80
Profit Growth %-29.00
Dividend Yield %0.08
Promoter Holding %60.89
FII Holding %19.93
DII Holding %
Beta0.62

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

HOLDConviction 57%

The picture

  • Promoter holding: 60.9%
  • RSI: 60
  • MACD: bullish
  • Price vs EMA21: above
  • 1-month return: +18.4%
  • 1-month vs NIFTY: +22.5% relative
  • Cup & Handle signal (setup quality 82%)
  • Pullback to 21-EMA signal (setup quality 71%)

Bull case

  • Promoter holding: 60.9%
  • RSI: 60
  • MACD: bullish
  • Price vs EMA21: above

Bear case

  • Revenue growth: 6.8% YoY
  • Profit growth: -29.0% YoY
  • Supertrend: bearish
  • Volatility: 49% annualized

Key risks

  • Weak fundamentals — technical strength may not sustain
  • Revenue growth: 6.8% YoY
  • Profit growth: -29.0% YoY

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹263.02
Stop Loss
₹223.28
risk 15.1%
Target 1 (1.5R)
₹322.63
+22.7%
Target 2 (3R)
₹382.24
+45.3%
Support (20d)
₹215.26
Resistance (52w)
₹332.20
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹39.74/share
ATR (volatility)
₹15.90
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹15.90). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental21
Technical75
Momentum89
Risk (safety)47

Peers — Pharma

CORONA 1.60%
87
GRANULES 1.12%
81
LAURUSLABS 1.23%
79
KPL 3.75%
79
DIVISLAB 1.23%
79
CAPLIPOINT 1.45%
78